Back to Journals » Core Evidence » Volume 9

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer

Authors Ravi S, Singal A

Received 28 February 2014

Accepted for publication 26 March 2014

Published 17 July 2014 Volume 2014:9 Pages 81—87


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Sujan Ravi,1 Ashwani K Singal2

1Department of Internal Medicine, 2Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not shown any added benefit over sorafenib. Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models. After its safety and pharmacological properties was studied in Phase I trials, a Phase II study evaluating the role of Regorafenib in patients with advanced HCC who progressed on sorafenib therapy demonstrated efficacy and a manageable safety profile. A Phase III trial is ongoing, and its result will help us better evaluate the role of Regorafenib in patients with advanced HCC.

Keywords: Regorafenib, hepatocellular carcinoma, HCC, advanced HCC, multikinase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]